Psychedelics Today, Author at PsyNews.com

Home Authors Posts by admin

2161 POSTS 0 COMMENTS

https://psynews.com

Meditation, Exploring Spiritual Traditions, and the Wisdom of Plant Medicine

Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated...

Difficult Conversations, the Need for Culturally Competent Care, and Why Representation...

Archetypes, Individuation, and the Shadow: Carl Jung’s Enduring Psychedelic Influence

Vital 4: Informational Session and Q+A, with David

Vital 4: Informational Session and Q+A, with Kyle

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with David

Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD

1...131415...217 Page 14 of 217

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Can Legalization Serve the Greater Good? The Ethical Challenges of Psychedelic...

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin

Meditation, Exploring Spiritual Traditions, and the Wisdom of Plant Medicine

Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated...

Difficult Conversations, the Need for Culturally Competent Care, and Why Representation...

Archetypes, Individuation, and the Shadow: Carl Jung’s Enduring Psychedelic Influence

Vital 4: Informational Session and Q+A, with David

Vital 4: Informational Session and Q+A, with Kyle

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with David

Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD

EDITOR PICKS

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Can Legalization Serve the Greater Good? The Ethical Challenges of Psychedelic...

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY